These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 30417231)

  • 21. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.
    Ahimastos AA; Walker PJ; Askew C; Leicht A; Pappas E; Blombery P; Reid CM; Golledge J; Kingwell BA
    JAMA; 2013 Feb; 309(5):453-60. PubMed ID: 23385271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
    Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K;
    JACC Heart Fail; 2017 May; 5(5):317-326. PubMed ID: 28449795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and Endovascular Treatment of Isolated Atherosclerotic Popliteal Artery Disease: Outcomes from the IPAD Multicenter Study.
    Spiliopoulos S; Kitrou P; Galanakis N; Papadimatos P; Katsanos K; Konstantos C; Palialexis K; Reppas L; Kehagias E; Karnabatidis D; Brountzos E; Tsetis D
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1481-1487. PubMed ID: 29992345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease.
    Giugliano G; Di Serafino L; Perrino C; Schiano V; Laurenzano E; Cassese S; De Laurentis M; Schiattarella GG; Brevetti L; Sannino A; Gargiulo G; Franzone A; Indolfi C; Piscione F; Trimarco B; Esposito G
    Int J Cardiol; 2013 Sep; 167(6):2566-71. PubMed ID: 22790191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication.
    Cosmi B; Conti E; Coccheri S
    Cochrane Database Syst Rev; 2001; (3):CD001999. PubMed ID: 11687006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
    Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Libby P; Thompson PD; Ghali M; Garza D; Berman L; Shi H; Buebendorf E; Topol EJ;
    JAMA; 2004 Nov; 292(18):2217-25. PubMed ID: 15536108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Conservative treatment of peripheral arterial disease].
    Espinola-Klein C; Weißer G
    Inn Med (Heidelb); 2022 Jun; 63(6):579-583. PubMed ID: 35532800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial.
    Musto C; Fiorilli R; De Felice F; Patti G; Nazzaro MS; Scappaticci M; Bernardi L; Violini R
    Int J Cardiol; 2013 Jun; 166(2):399-403. PubMed ID: 22093961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
    Ahimastos AA; Latouche C; Natoli AK; Reddy-luthmoodoo M; Golledge J; Kingwell BA
    Circ Res; 2014 Mar; 114(7):1144-55. PubMed ID: 24397981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
    Gaggin HK; Liu Y; Lyass A; van Kimmenade RR; Motiwala SR; Kelly NP; Mallick A; Gandhi PU; Ibrahim NE; Simon ML; Bhardwaj A; Belcher AM; Harisiades JE; Massaro JM; D'Agostino RB; Januzzi JL
    Circulation; 2017 Jan; 135(2):116-127. PubMed ID: 27881568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease.
    Kalbaugh CA; Taylor SM; Blackhurst DW; Dellinger MB; Trent EA; Youkey JR
    J Vasc Surg; 2006 Aug; 44(2):296-302; discussion 302-3. PubMed ID: 16814976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.